Excelsoft Technologies IPO Day 1: Check Subscription Status, Key Highlights, and More

19 November 2025
1 min read
Excelsoft Technologies IPO Day 1: Check Subscription Status, Key Highlights, and More
whatsapp
facebook
twitter
linkedin
telegram
copyToClipboard

Global vertical SaaS company Excelsoft Technologies’s Initial Public Offering (IPO) is open for public subscription today, November 19, 2025. One day prior to the IPO opening, the company raised ₹150 crore from anchor investors on November 18, 2025. 

Excelsoft Technologies IPO: Issue Details

Excelsoft Technologies IPO is a book-building issue of ₹500 crores, consisting of a fresh issue of ₹180 crores and an offer for sale of ₹320 crores by promoter Pedanta Technologies Private Limited.   

The price band is set between ₹114 and ₹120 per share. The basis of allotment will be finalised by November 24, 2025, and the tentative listing date on BSE and NSE is November 26, 2025. 

 Excelsoft Technologies IPO Day 1 Subscription Status

[19-November-2025 11:00:00 hrs]

Investor Category

Subscription (Times)

Qualified Institutional Buyers (QIBs)

0.00

Non-Institutional Investors

0.49

Retail Individual Investors (RIIs)

0.54

Total

0.37

Utilisation of IPO Proceeds

The net proceeds from the fresh will be used to 

  • Fund capital expenditure towards 
    • Purchase of land and construction of a new building located in the Mysore District
    • Upgrading and external electrical systems at the existing facility
    • Upgrading the Company’s IT Infrastructure 
  • General corporate purposes

Excelsoft Technologies Business Overview

Excelsoft Technologies is a global vertical SaaS provider specialising in technology solutions for the learning, training, and assessment ecosystem. The company also offers a comprehensive range of learning solutions that support digital content distribution, subscription management, interactive learning experiences, and institutional training needs.

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.

To read the RA disclaimer, please click here

Do you like this edition?